Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptides to screen for antibacterial compounds and methods for treatment of individuals having a need to inhibit tRNA synthetase polypeptides.

Abstract: Novel fibronectin binding protein B polypeptides and DNA (RNA) encoding such novel fibronectin binding protein B and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such novel fibronectin binding protein B for the treatment of infection, particularly bacterial infections. Antagonists against such novel fibronectin binding protein B and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of novel fibronectin binding protein B nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding novel fibronectin binding protein B family and for detecting the polypeptide in a host.

Abstract: The invention provides hisS polypeptides and DNA (RNA) encoding hisS polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing hisS polypeptides to screen for antibacterial compounds.

Abstract: Azetidinone derivatives of formula (I) in which R.sup.1 and R.sup.2, which may be the same or different, is each selected from hydrogen or C.sub.(1-8) alkyl; R.sup.3 is C.sub.(1-8) alkyl or C.sub.(3-8) cycloalkyl each of which may be optionally substituted; X is a linker group; Y is an aryl group; and n is 0, 1 or 2; and excluding benzyl (4-methylthio-2-oxo-azetidin-1-yl)acetate are inhibitors of the enzyme Lp PLA2 and are of use in therapy, in particular treating atherosclerosis.

Abstract: The invention provides Histidine Kinase polypeptides and polynucleotides encoding Histidine Kinase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Histidine Kinase polypeptides or polynucleotides to screen for antibacterial compounds.

Abstract: A process for preparing certain substituted benzopyran compounds of formula (I) ##STR1## is disclosed.

Abstract: Compounds of formula (I) in which B is oxygen, CR.sup.17 R.sup.18 or NR.sup.19 where R.sup.17, R.sup.18 and R.sup.19 are independently hydrogen or C.sub.1-6 alkyl or B is a group S(O).sub.b where b is 1, 2, or 3; and R.sup.6 is a group --(CH.sub.2).sub.p --R.sup.15 where R.sup.15 is OR.sup.16 or SR.sup.16 is hydrogen or C.sub.1-6 alkyl or R.sup.15 is NR.sup.10 R.sup.11 where R.sup.10 and R.sup.11 are as defined for R.sup.1 ; have been found to exhibit 5TH.sub.1B antagonist activity.

Abstract: Aminophosphonates alpha substituted by phenol groups of formula (I) have lipoprotein(a) lowering activity.

Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.

Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta.-lactam antibiotics against many .beta.-lactamase producing bacteria.

Abstract: The invention provides glyS (beta) and glyS (alpha) polypeptides and DNA (RNA) encoding glyS (beta) and glyS (alpha) polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing glyS (beta) and glyS (alpha) polypeptides to screen for antibacterial compounds.

Abstract: A pump dispenser suitable for striped toothpaste, comprising a pump head [1] and a replaceable reservoir [2] for the toothpaste, in which the toothpaste is packed in radially disposed segments, and the reservoir is locked against rotation relative to the pump head.

Abstract: The invention provides leuS polypeptides and DNA (RNA) encoding leuS polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing leuS polypeptides to screen for antibacterial compounds.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta.-lactam antibiotics against many .beta.-lactamase producing bacteria.

Abstract: A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a .beta.-lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, ##STR1## wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R.sub.1 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C.sub.1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C.sub.1-6)alkylcarbonyloxy, (C.sub.1-6)alkoxycarbonyl, formyl or (C.sub.1-6)alkylcarbonyl group, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl(C.sub.1-6)alkyl, heterocyclyl or heterocyclyl(C.sub.1-6)alkyl; R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.

Abstract: This invention provides compounds of formula (I):A.sup.1 --X--(CH.sub.2).sub.n --O--A.sup.2 --A.sup.3 --Y.R.sup.2(I)or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein A.sup.1, A.sup.2, A.sup.3, R.sup.2, X, Y and n are as defined herein; pharmaceutical composition comprising such compounds and the use of such a compounds for treating hyperglycemia.

Abstract: A computational method maximizing open reading frame length in an assembly consensus sequence is provided. Systems employing the method are also provided.

Abstract: This invention relates to compounds of formula (I): ##STR1## which are useful as modulators of D.sub.3 receptors, in particular in the treatment of psychoses.

Abstract: The invention provides asnS polypeptides and DNA (RNA) encoding asnS polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing asnS polypeptides to screen for antibacterial compounds.